Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Eukaryotic Gene Expression
Factor de Impacto: 1.841 Factor de Impacto de 5 años: 1.927 SJR: 0.627 SNIP: 0.516 CiteScore™: 1.96

ISSN Imprimir: 1045-4403
ISSN En Línea: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2018025121
pages 373-384

Interferon-Free Regimen for Hepatitis C: Insight and Management

Muhammad Shareef Masoud
Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Pakistan
Usman Ali Ashfaq
Department of Bioinformatics & Biotechnology, Government College University, 38000 Faisalabad, Pakistan
Hina Khalid
Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Pakistan

SINOPSIS

The rapid development of direct-acting antiviral agents (DAA) for hepatitis C virus (HCV) therapy dramatically altered the treatment landscape of this disease. The DAA regimen is associated with various advantages including high sustained virological response (SVR) with minimum side effects and low pill load and specific inhibition of viral replication, which lowers dependence on the host cell. This regimen has substantially replaced conventional (interferon) therapy with high cure rates (> 90%) in most HCV populations. This review provides insight into clinical studies of NS3/4A protease inhibitors, NS5B viral polymerase inhibitor (nucleotide and non-nucleotide), and NS5A inhibitors, alone and in combination.


Articles with similar content:

Anti-Inflammatory and Anti-Cancer Activity of Boswellic Acids from Frankincense (Boswellia serrata Roxb. et Colebr, B. carterii Birdw.)
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Henry Johannes Greten, Thomas Efferth
Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Anne Arah Cho, Benjamin Bonavida
YY1 as a Therapeutic Target in Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.1, 2010, issue 1-2
Khimara Naidoo, Richard J. Byers
RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF-κB/Snail/YY1/RKIP Resistance-Driver Loop
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Benjamin Bonavida
Oral Controlled-Release Formulation in Veterinary Medicine
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.23, 2006, issue 3
Stefan Soback, Eran Lavy, Amir Steinman